Pre-Targeting Platform
Multiple Solid Tumors
PreclinicalUnder evaluation
Key Facts
Indication
Multiple Solid Tumors
Phase
Preclinical
Status
Under evaluation
Company
About Perspective Therapeutics
Perspective Therapeutics is on a mission to transform cancer treatment with its innovative, image-guided targeted alpha-particle therapy platform. Formed in February 2023 from the merger of Viewpoint Molecular Targeting and Isoray, the company leverages proprietary Pb-212-based radiotherapies and a matched imaging agent (Pb-203) for a precise theranostic approach. Its clinical pipeline includes programs for neuroendocrine tumors (VMT-α-NET), melanoma (VMT01/02), and fibroblast activation protein (PSV359) positive solid tumors, positioning it at the forefront of the next generation of radiopharmaceuticals.
View full company profileTherapeutic Areas
Other Multiple Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| BAY 1817080 | Bayer | Phase 1 |
| Zanzalintinib + nivolumab | Exelixis | Phase 1b/2 |
| Zanzalintinib + atezolizumab | Exelixis | Phase 1b/2 |
| XL309 | Exelixis | Phase 1 |
| XB010 | Exelixis | Phase 1 |
| XB628 | Exelixis | Phase 1 |
| XB371 | Exelixis | Phase 1 |
| ADU-1805 | Exelixis | Phase 1 |
| Multiple Preclinical Programs | Perspective Therapeutics | Preclinical |
| VDC Platform | Aura Biosciences | Pre-clinical/Discovery |
| MGC026 | MacroGenics | Phase 1 |
| MGC028 | MacroGenics | Phase 1 |